Allogene Therapeutics Stock News

Michael Platts wealth swelled even further last year as the billionaire continues to outperform most hedge funds with the freedom to take on riskier bets after returning clients money.

Allogene Therapeutics Inc (ALLO) shares closed today 11.0% higher than it did at the end of yesterday. The stock is currently down 11.0% year-to-date, down 59.0% over the past 12 months, and down 46.9% over the past five years. Today, the Dow Jones Industrial Average fell 0.6%, and the S&P 500 rose 0.0%. Trading Activity Shares traded as high as $13.87 and as low as $11.54 this week.Shares closed 66.1% below its 52-week high and 15.1% above its 52-week low.Trading volume this week was 43.6% lower than the 10-day average and 3.2% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 798.0% The company's stock price performance over the past 12 months lags the peer average by 526.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

In this article you are going to find out whether hedge funds think Allogene Therapeutics, Inc. (NASDAQ:ALLO) is a good investment right now.

There isn't much development since the October clinical hold.

Allogene Therapeutics has brokered an exclusive collaboration and global license agreement with Antion Biosciences for the latters miRNA technology to advance multiplex gene silencing.

Allogene Therapeutics Inc (ALLO) shares closed 5.4% lower than its previous 52 week low, giving the company a market cap of $1B. The stock is currently down 9.8% year-to-date, down 51.7% over the past 12 months, and down 46.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 59.9% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 3654.9% The company's stock price performance over the past 12 months lags the peer average by 596.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

(RTTNews) - Cellectis said its licensed partner, Allogene Therapeutics Inc. (ALLO) announced that the U.S. Food and Drug Administration has lifted the clinical hold on its cancer drug trial. Allogene reported that the FDA''s investigations concluded that the chromosomal abnormality was unrelated to TALEN gene editing or Allogene''s manufacturing

The removal of an FDA clinical hold on all five AlloCAR T clinical trials was not enough to boost Allogene Therapeutics as the stock closed down ~9.4%.

Allogene reported that Chromosomal Abnormality Was Not the Result of TALEN® Gene Editing or Allogene''s Manufacturing Process Allogene to Initiate a Phase 2 Pivotal Clinical Trial of ALLO-501A in Relapsed/Refractory Large B-cell Lymphoma Mid-year 2022 Pending FDA Discussion NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cellectis (NASDAQ: CLLS ), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today stated that its licensed partner, Allogene Therapeutics, Inc. (NASDAQ: ALLO ) announced that the U.S. Food and Drug Administration (FDA) has lifted the hold on its clinical trials. The FDA had placed a clinical hold on all five of Allogene''s clinical trials on October 7, 2021 following a report of a chromosomal abnormality detected in ALLO-501A CAR+ T-cells from a single patient enrolled in Allogene''s ALPHA2 study. Allogene reported today that the investigations concluded that the chromosomal abnormality was unrelated to TALEN® gene editing or Allogene''s manufacturing process and had no clinical significance.

Allogene Therapeutics (ALLO) perks up 2.8% premarket after announcing that the FDA has removed the clinical hold on all of its AlloCAR T clinical trials.Earlier on October 7, 2021 the

Investigation Confirmed the Chromosomal Abnormality in a Single Patient was Not Observed in Any AlloCAR T Product and Not Related to Allogene Manufacturing Process or TALEN ® Gene Editing Clinical Trials Across the AlloCAR T Platform to Resume Pivotal Phase 2 Trial of ALLO-501A in Relapsed/Refractory Large B Cell Lymphoma Expected to Commence in Mid-Year 2022 Pending FDA Discussions Company to Host Conference Call Today at 8:30 am PT/11:30 am ET SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ: ALLO ), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on all of the Company''s AlloCAR T clinical trials. Allogene previously announced on October 7, 2021 that the FDA had placed a hold on all five of the Company''s AlloCAR T clinical trials based on a report of a chromosomal abnormality detected post-AlloCAR T administration in a single patient treated with ALLO-501A in the ALPHA2 study.

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA

In last trading session, Allogene Therapeutics Inc. (NASDAQ:ALLO) saw 1.25 million shares changing hands with its beta currently measuring 0. Companys recent per share price level of $15.51 trading at -$0.13 or -0.83% at ring of the bell on the day assigns it a market valuation of $2.07B. That closing price of ALLOs stock is Allogene Therapeutics Inc. (NASDAQ:ALLO) Has Risen By -15.61 Percent Over The Past 30 Days: Will It Continue? Read More »

Allogene Therapeutics, Inc. (NASDAQ:ALLO) has received a consensus recommendation of Buy from the sixteen ratings firms that are covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. The average 12 month price objective among brokerages that have []

In the last trading session, 4.26 million shares of the Allogene Therapeutics Inc. (NASDAQ:ALLO) were traded. Most recently the companys share price was $14.30, and it changed around $0.19 or 1.35% from the last close, which brings the market valuation of the company to $2.04B. ALLO currently trades at a discount to its 52-week high Allogene Therapeutics Inc. (NASDAQ: ALLO) Stock Forecast 2021: Profitable With Bullish Signals Read More »